BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
18 sept. 2024 08h00 HE
|
BiomX
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 08h00 HE
|
BiomX
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024
03 sept. 2024 08h00 HE
|
BiomX
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
16 août 2024 10h55 HE
|
BiomX
In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units...
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
15 août 2024 06h30 HE
|
BiomX
BiomX anticipates reporting important results in 2025 for two clinical assets from the Company’s leading phage therapy pipeline Recent stockholder vote approves conversion of Series X Non-Voting...
BiomX Inc. Announces 1-for-10 Reverse Stock Split
15 août 2024 06h30 HE
|
BiomX
GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
08 août 2024 07h00 HE
|
BiomX
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
29 juil. 2024 07h00 HE
|
BiomX
GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
10 juil. 2024 06h30 HE
|
BiomX
GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
30 mai 2024 16h50 HE
|
BiomX
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...